Torl Biotherapeutics, founded in 2018 and based in Culver City, California, is a clinical-stage biopharmaceutical company dedicated to developing novel antibody-based therapeutics for cancer treatment. The company's core mission is to advance innovative biologics that address unmet medical needs in oncology. Torl Bio currently has three therapeutics in Phase 1 clinical trials targeting non-small cell lung cancer (NSCLC), gastric, pancreatic, and ovarian cancers.
Notable affiliated people and investors include leading experts in oncology and biopharmaceuticals, although specific names are not disclosed. Key achievements include progressing multiple therapeutic candidates into early-stage clinical trials, demonstrating their commitment to pioneering cancer treatments. Torl Biotherapeutics has made a significant impact by focusing on difficult-to-treat cancers, aiming to improve patient outcomes through cutting-edge antibody-based therapies.
